Department of General Internal Medicine, Mater Hospital Brisbane, Brisbane, Queensland, Australia
Department of Nephrology, Mater Hospital Brisbane, Brisbane, Queensland, Australia.
BMJ Case Rep. 2023 Sep 12;16(9):e254715. doi: 10.1136/bcr-2023-254715.
Acute interstitial nephritis (AIN) is a common cause of acute kidney injury and renal failure. It is typically drug induced but can also be idiopathic or secondary to chronic infective or inflammatory conditions. Recent case reports suggest vedolizumab can be a causative agent for AIN. We report the case of a young man who presented with renal failure, fevers and constitutional symptoms. He had a complex history of refractory ulcerative colitis, prior colectomy and ileo-pouch-anal anastomosis with recurrent pouchitis. He had been receiving regular vedolizumab infusions for 6 months by the time of his presentation. A renal biopsy 4 months into his follow-up demonstrated AIN. Steroid prophylaxis with vedolizumab was trialled but ultimately failed, with worsening AIN and incomplete renal function recovery. To our knowledge, this is the first case of vedolizumab-induced AIN demonstrating a failure of steroid prophylaxis to prevent recurrence of AIN following vedolizumab rechallenge.
急性间质性肾炎(AIN)是急性肾损伤和肾衰竭的常见原因。它通常是由药物引起的,但也可能是特发性的,或继发于慢性感染或炎症性疾病。最近的病例报告表明,vedolizumab 可能是 AIN 的致病因素。我们报告了一例年轻男性,他因肾衰竭、发热和全身症状就诊。他有溃疡性结肠炎、先前的结肠切除术和回肠-袋-肛门吻合术以及反复 pouchitis 的复杂病史。在就诊时,他已经接受了 6 个月的常规 vedolizumab 输注。他随访 4 个月时的肾活检显示 AIN。vedolizumab 预防性使用类固醇进行了尝试,但最终失败,AIN 恶化,肾功能不完全恢复。据我们所知,这是首例 vedolizumab 诱导的 AIN 病例,表明在 vedolizumab 再挑战后,类固醇预防未能预防 AIN 的复发。